SeaStar Medical Holding Corp (ICU): Results of Operations and Financial Condition
SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_973548.htm EXHIBIT 99.1 - Q1 2026 EARNINGS RELEASE ex_973548.htm Exhibit 99.1 SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates Added 3 top-rated children ’ s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) cust
How this was made
The 30-second read
Why it matters
Key trading-relevant updates are QUELIMMUNE revenue growth, NEUTRALIZE-AKI enrollment progress toward 339 patients, and CMS ICD-10-PCS codes expected to take effect Oct 1, 2026, which may improve billing and adoption.
Market read
Investors get a fresh checkpoint on commercialization traction (QUELIMMUNE revenue), trial momentum (223/339 enrolled), and reimbursement readiness (ICD-10-PCS effective Oct 1, 2026), alongside updated loss and cash figures.
What to watch
Cash declined to $7.0M from $12.0M at year-end, and R&D and G&A rose, which could increase financing needs before PMA milestones.
Background
This is an SEC 8-K with Exhibit 99.1 covering SeaStar Medical’s Q2 2026 financial results and business updates for QUELIMMUNE and the NEUTRALIZE-AKI pivotal trial.
Ticker impact
SeaStar Medical reported Q2 2026 results and said QUELIMMUNE net revenue rose to about $0.6M, plus NEUTRALIZE-AKI enrollment reached 223 of 339.
Bias modestly positive, with upside skew if investors view the ICD-10-PCS rollout and trial enrollment pace as de-risking the 2027 PMA path.
New disclosures include quarterly revenue, R&D and cash burn, trial enrollment progress (223/339), and CMS ICD-10-PCS codes expected to take effect Oct 1, 2026, all of which affect commercialization and regulatory-readiness narratives.
Market effects
Reinforces investor focus on reimbursement enablement (ICD-10-PCS) and enrollment pace as key de-risking signals for small-cap medtech/biotech.
Limited, company-specific US healthcare impact.
Low, primarily US reimbursement and FDA PMA timeline driven.
Counterpoint
Revenue growth may still be too small in absolute dollars to offset dilution risk, and the adult AKI PMA timeline remains contingent on trial outcomes.
Key entities
- issuerSeaStar Medical Holding Corp
Commercial-stage healthcare company focused on organ-failure treatments; subject of the 8-K.
- productQUELIMMUNE (SCD-PED)
Selective cytopheretic device therapy being commercialized for pediatric AKI in ICU settings.
- clinical_trialNEUTRALIZE-AKI
Pivotal trial evaluating SCD therapy in adult AKI patients on continuous renal replacement therapy.
- regulatory_billingCMS ICD-10-PCS codes
Procedure coding system codes enabling standardized inpatient billing for SCD therapy, expected to take effect Oct 1, 2026.
- regulatory_pathwayFDA PMA application
Planned premarket approval submission for adult AKI indication, contingent on trial outcome.
